Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    75.0%

    Based on 3 completed trials

    Completion Rate
    75%(3/4)
    Active Trials
    0(0%)
    Results Posted
    133%(4 trials)
    Terminated
    1(20%)

    Phase Distribution

    Phase 2
    5
    100%

    Phase Distribution

    0

    Early Stage

    5

    Mid Stage

    0

    Late Stage

    Phase Distribution5 total trials
    Phase 2Efficacy & side effects
    5(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    60.0%

    3 of 5 finished

    Non-Completion Rate

    40.0%

    2 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(3)
    Terminated(2)

    Detailed Status

    Completed3
    Withdrawn1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    75.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 25 (100.0%)

    Trials by Status

    withdrawn120%
    completed360%
    terminated120%

    Recent Activity

    0 active trials
    Showing 5 of 5
    completedphase_2

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

    NCT00665626
    completedphase_2

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

    NCT00665925
    completedphase_2

    Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

    NCT00706342
    terminatedphase_2

    Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

    NCT00805467
    withdrawnphase_2

    Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

    NCT00752999

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT00665626Phase 2

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

    Completed
    NCT00665925Phase 2

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

    Completed
    NCT00706342Phase 2

    Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

    Completed
    NCT00805467Phase 2

    Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

    Terminated
    NCT00752999Phase 2

    Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

    Withdrawn

    All 5 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    5